Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022

News provided by

Dec 07, 2022, 16:05 ET

Live Conference Call and Webcast at 8:30 AM ET

PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, dial (866) 374-5140 (U.S.) or (404) 400-0571 (International) and enter PIN 79797687#. The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]

Media:
Sarah Mathieson
SVP, Corporate Affairs
[email protected]

SOURCE Eiger BioPharmaceuticals, Inc.